Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Overview
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Companies Involved in Therapeutics Development
Alphamab Oncology
Anthos Therapeutics Inc
Aronora Inc
Bayer AG
Bio Products Laboratory Ltd
Bioxodes SA
Bristol-Myers Squibb Co
Cambryn Biologics LLC
Chi Resources Pharmaceutical Group Ltd
eXithera Pharmaceuticals Inc
Ionis Pharmaceuticals Inc
Jiangsu Hengrui Medicine Co Ltd
KLUS Pharma Inc
Merck & Co Inc
Mochida Pharmaceutical Co Ltd
Novartis AG
Ono Pharmaceutical Co Ltd
Regeneron Pharmaceuticals Inc
Shenzhen Salubris Pharmaceuticals Co Ltd
Sichuan Kelun Pharmaceutical Co Ltd
Siromics Ltd
Suzhou Ribo Life Sciences Co Ltd
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Drug Profiles

7300 Series - Drug Profile
Product Description
Mechanism Of Action
A-186 - Drug Profile
Product Description
Mechanism Of Action
History of Events
A-336 - Drug Profile
Product Description
Mechanism Of Action
AB-023 - Drug Profile
Product Description
Mechanism Of Action
History of Events
abelacimab - Drug Profile
Product Description
Mechanism Of Action
History of Events
asundexian - Drug Profile
Product Description
Mechanism Of Action
History of Events
BMS-962212 - Drug Profile
Product Description
Mechanism Of Action
History of Events
BMS-986209 - Drug Profile
Product Description
Mechanism Of Action
History of Events
coagulation factor XI (human) - Drug Profile
Product Description
Mechanism Of Action
History of Events
coagulation factor XI (human) - Drug Profile
Product Description
Mechanism Of Action
History of Events
coagulation factor XI (human) - Drug Profile
Product Description
Mechanism Of Action
History of Events
EP-7041 - Drug Profile
Product Description
Mechanism Of Action
History of Events
fesomersen sodium - Drug Profile
Product Description
Mechanism Of Action
History of Events
IONIS-FXIRx - Drug Profile
Product Description
Mechanism Of Action
History of Events
Ir-CPI - Drug Profile
Product Description
Mechanism Of Action
History of Events
KN-060 - Drug Profile
Product Description
Mechanism Of Action
milvexian - Drug Profile
Product Description
Mechanism Of Action
History of Events
MK-2060 - Drug Profile
Product Description
Mechanism Of Action
History of Events
MR-1007 - Drug Profile
Product Description
Mechanism Of Action
History of Events
NIP-003 - Drug Profile
Product Description
Mechanism Of Action
ONO-7684 - Drug Profile
Product Description
Mechanism Of Action
History of Events
osocimab - Drug Profile
Product Description
Mechanism Of Action
History of Events
REGN-9933 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SAL-0104 - Drug Profile
Product Description
Mechanism Of Action
SHR-2285 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SKB-336 - Drug Profile
Product Description
Mechanism Of Action
Small Molecule to Inhibit Coagulation Factor XI for Bleeding and Clotting Disorders - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit Factor XI for Bleeding And Clotting Disorders - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit Factor XIa for Arterial Thrombosis - Drug Profile
Product Description
Mechanism Of Action
History of Events
SR-059 - Drug Profile
Product Description
Mechanism Of Action
STP-122G - Drug Profile
Product Description
Mechanism Of Action
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Dormant Products
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Discontinued Products
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Product Development Milestones
Featured News & Press Releases
Aug 28, 2022: Late-breaking results from phase 2 AXIOMATIC-SSP study of Milvexian, an investigatiol oral factor XIa inhibitor, show favorable antithrombotic profile in combition with dual antiplatelet therapy
Aug 25, 2022: Anthos therapeutics launches second phase 3 clinical trial of its dual-acting Factor XI inhibitor, abelacimab
Aug 23, 2022: Merck receives fast track desigtion from the U.S. FDA for MK-2060, an investigatiol anticoagulant therapy
Aug 22, 2022: Bayer to present data from cardiovascular portfolio, including a late-breaking presentation from new phase IIb data from PACIFIC Trial program for the oral factor XIa Inhibitor asundexian
Jul 29, 2022: Ionis reports positive Phase IIb data of fesomersen for thrombosis
Jul 28, 2022: Phase 2b studies of investigatiol selective coagulation modulator osocimab in patients with advanced rel disease completed
Jul 13, 2022: Four new sets of pre-clinical data further expands the evidence supporting abelacimab
Jul 11, 2022: Anthos Therapeutics announces that abelacimab has received FDA fast track desigtion for the treatment of thrombosis associated with cancer
Jun 13, 2022: Anthos Therapeutics to host discussion with global experts on the promise of Factor XI Inhibition at the 2022 BIO Intertiol Convention
May 05, 2022: Abelacimab: first factor XI inhibitor to enroll patients in a phase 3 clinical trial
Apr 11, 2022: Announcement of Haisco on obtaining the drug clinical trial approval notice for HSK36273
Apr 03, 2022: Bayer presents positive results from first Phase 2b trial on safety of asundexian in patients with atrial fibrillation
Mar 29, 2022: Bayer to present data on Asundexian at the American College of Cardiology’s 71st Annual Scientific Session
Feb 10, 2022: Bayer receives FDA Fast Track Desigtion for asundexian stroke program
Jan 18, 2022: Haisco announces notice of acceptance for clinical trial application of HSK36273 for innovative drug injection
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Alphamab Oncology, 2022
Pipeline by Anthos Therapeutics Inc, 2022
Pipeline by Aronora Inc, 2022
Pipeline by Bayer AG, 2022
Pipeline by Bio Products Laboratory Ltd, 2022
Pipeline by Bioxodes SA, 2022
Pipeline by Bristol-Myers Squibb Co, 2022
Pipeline by Cambryn Biologics LLC, 2022
Pipeline by China Resources Pharmaceutical Group Ltd, 2022
Pipeline by eXithera Pharmaceuticals Inc, 2022
Pipeline by Ionis Pharmaceuticals Inc, 2022
Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
Pipeline by KLUS Pharma Inc, 2022
Pipeline by Merck & Co Inc, 2022
Pipeline by Mochida Pharmaceutical Co Ltd, 2022
Pipeline by Novartis AG, 2022
Pipeline by Ono Pharmaceutical Co Ltd, 2022
Pipeline by Regeneron Pharmaceuticals Inc, 2022
Pipeline by Shenzhen Salubris Pharmaceuticals Co Ltd, 2022
Pipeline by Sichuan Kelun Pharmaceutical Co Ltd, 2022
Pipeline by Sirnaomics Ltd, 2022
Pipeline by Suzhou Ribo Life Sciences Co Ltd, 2022
Dormant Projects, 2022
Discontinued Products, 2022